Hybio Pharmaceutical Co., Ltd. Class A

Hybio Pharmaceutical Co., Ltd. Class A

SSZSE:300199
22.20
CNY
+0.17
(+0.77%)
0.45EPS
53.02P/E
21.13BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.37
0.46
0.86
0.97
1.36
1.37
0.67
0.78
0.72
0.8
0.49
0.68
1.06
1.71
Basic EPS, GAAP
0.16
0.19
0.34
0.33
0.36
-0.37
-0.96
-0.66
0.03
-0.42
-0.58
-0.2
0.04
0.45
Free Cash Flow per Basic Share
-0.18
0.08
-0.25
0.2
0.01
-0.35
-0.51
-0.21
-0.04
-0.2
-0.1
0.06
- -
- -
Dividend per Share
0.02
0.01
0.08
0.07
0.14
0.27
0.12
0.11
0.11
0.13
0.13
0.13
0.1
0.11
Book Value per Share
1.41
1.62
2.96
3.93
4.16
3.65
2.43
1.79
1.73
1.39
0.86
0.66
0.7
1.21
Tangible Book Value per Share
1.33
1.54
1.39
2.43
2.74
2.72
1.83
1.19
1.21
0.83
0.37
0.17
0.19
0.72
Basic Weighted Avg Shares
812
903
898
885
916
921
922
923
1,027
882
886
868
914
891
Sales/Revenue/Turnover
301
419
768
855
1,246
1,264
614
722
736
704
431
590
966
1,526
Operating Margin (%)
45.55
44.63
48.24
42.15
34.47
19.05
-70.93
-10.45
-12.35
-12.35
-65.25
3.54
22.61
35.23
Depreciation Expense
13
30
82
91
96
97
101
105
136
141
156
148
133
- -
Net Income, GAAP
130
172
305
292
330
-341
-885
-609
31
-371
-514
-174
37
402
Effective Tax Rate (%)
12.12
7.93
9.76
5.58
5.94
- -
- -
- -
15.57
- -
- -
- -
47.02
8.77
Profit Margin (%)
43.11
40.9
39.74
34.14
26.46
-26.95
-144.05
-84.44
4.19
-52.61
-119.12
-29.42
3.78
26.34
Working Capital
591
873
560
1,511
1,734
2,189
757
-60
411
-336
-740
-962
-1,258
-681
LT Debt
- -
199
398
418
455
1,348
1,263
1,155
1,373
1,023
939
861
623
930
Total Equity
1,124
1,296
2,637
3,605
3,885
3,392
2,233
1,678
1,648
1,297
783
597
630
1,086
Return on Invested Capital (%)
11.62
12.86
12.77
7.31
7.71
- -
- -
- -
1.1
- -
- -
- -
2.03
13.52
Return on Capital (%)
11.52
13.93
14.49
9.23
8.15
- -
- -
- -
3.03
- -
- -
- -
3.7
16.4
Return on Common Equity (%)
12.14
14.18
15.53
9.35
8.8
-9.37
-31.49
-31.53
1.91
-25.96
-50.64
-25.97
6.13
44.77

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,000
966
1,071
LT Borrowings
956
947
930
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
883
883
883
Market Capitalization
16,676
19,502
21,127

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
659
738
1,112
Cash, Cash Equivalents & STI
109
151
206
Accounts Receivable, Net
170
145
347
Inventories
337
403
498
Total Current Liabilities
1,538
1,603
1,794
Payables & Accruals
- -
- -
- -
ST Debt
1,000
966
1,071
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-10.82%
-16.19%
5.51%
Free Cash Flow
-475.74%
-14.99%
-100.92%
Net Income, GAAP
-162.27%
-311.29%
-121.06%
Sales/Revenue/Turnover
8.41%
11.89%
63.73%
Total Cash Common Dividend
11.39%
-1.64%
-15.13%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
150
105
120
215
590
2025
310
239
- -
283
966
2026
299
389
554
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
- -
-0.03
-0.16
-0.2
2025
0.08
0.09
- -
-0.04
0.04
2026
0.14
0.12
0.23
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.02
0.03
0.04
0.13
2025
0.02
0.02
- -
0.04
0.1
2026
0.02
0.02
0.02
- -
- -

Company Description

CEO
Shaogui Zeng
Full Time Employees
1,226
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hanyu Innovation Industry Building Shenzhen GD China 518110
IPO Date
Mar 25, 2011
Business
Hybio Pharmaceutical Co., Ltd. is engaged in the extensive research, development, production, and distribution of a diverse portfolio of therapeutic peptides and oligonucleotide drugs across global markets. The company's innovative product lines include advanced peptide formulations and active pharmaceutical ingredients addressing significant health challenges such as diabetes and metabolic disorders with offerings like liraglutide, semaglutide, and exenatide. They also provide treatments for conditions impacting the digestive and endocrine systems, including terlipressin, desmopressin, and linaclotide, alongside solutions for obstetrics and gynecology like ganirelix, cetrorelix, and atosiban. Furthermore, Hybio extends its expertise through comprehensive contract research organization (CRO) and contract development and manufacturing organization (CDMO) services, encompassing peptide API synthesis, formulation development, and regulatory support that meets stringent global GMP standards, including those of the EU and FDA. The company, established in 1998, is headquartered in Shenzhen, China, and continues to expand its reach and capabilities, notably securing significant funding and forging new partnerships in 2025 to advance its weight-loss drug pipeline and international collaborations.